Statistiche di base
| CIK | 941020 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to GeneLink, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| February 25, 2015 |
GNLKQ / GeneLink, Inc. 15-12G - - 15-12G 1 form15.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND (15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-30518 GENELINK, INC. (Exact name of registrant as s |
|
| April 22, 2014 |
United States Securities and Exchange Commission Washington, DC 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: April 22, 2014 GeneLink, Inc. |
|
| April 1, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) [X] Form 10-K [] Form 20-F [] Form 11-K [] Form 10-Q [] Form N-SAR For Period Ended: December 31, 2013 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q [] Transition Report on Form N-SAR For |
|
| December 17, 2013 |
SUBSIDIARIES OF THE REGISTRANT EXHIBIT 21 SUBSIDIARIES OF THE REGISTRANT The following is a list of subsidiaries of GeneLink, Inc. Dermagenetics, Inc., a Delaware corporation Helix Health Solutions, LLC, a Florida limited liability company |
|
| December 17, 2013 |
Annual Report - GENELINK 10-K/A 12-31-2012 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑K/A (Amendment No.2) (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 OR o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-30518 GENELINK, INC. (Exac |
|
| November 27, 2013 |
Annual Report - GENELINK INC 10-K A NO 1 12-31-2012 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10?K/A (Amendment No.1) (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 OR o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-30518 GENELINK, INC. (Exac |
|
| November 27, 2013 |
SUBSIDIARIES OF THE REGISTRANT EX-21 2 ex21.htm EXHIBIT 21 EXHIBIT 21 SUBSIDIARIES OF THE REGISTRANT The following is a list of subsidiaries of GeneLink, Inc. Dermagenetics, Inc., a Delaware corporation Helix Health Solutions, LLC, a Florida limited liability company |
|
| November 14, 2013 |
Quarterly Report - GENELINK INC 10-Q 9-30-2013 U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-30518 GENELINK, INC. (Exact name of |
|
| November 14, 2013 |
United States Securities and Exchange Commission Washington, DC 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: November 14, 2013 GeneLink, Inc. |
|
| November 13, 2013 |
November 12, 2013 Ms. Linda Cvrkel Branch Chief United States Securities and Exchange Commission Washington, D.C. 20549 Re: GeneLink, Inc. Form 10-K for the Year Ended December 31, 2012 Filed April 1, 2013 Form 10-Q for the Quarter Ended March 31, 2013 Filed May 15, 2013 File No. 000-30518 Dear Ms. Cvrkel: We have responded to your comments below. Form 10-K for the Year Ended December 31, 2012 Aud |
|
| October 29, 2013 |
October 29, 2013 Ms. Linda Cvrkel Branch Chief United States Securities and Exchange Commission Washington, D.C. 20549 Re: GeneLink, Inc. Form 10-K for the Year Ended December 31, 2012 Filed April 1, 2013 Form 10-Q for the Quarter Ended March 31, 2013 Filed May 15, 2013 File No. 000-30518 Dear Ms. Cvrkel: This letter is to confirm the discussion between Chrissy Hembree, Controller, and Claire Erla |
|
| September 30, 2013 |
September 27, 2013 Ms. Linda Cvrkel Branch Chief United States Securities and Exchange Commission Washington, D.C. 20549 Re: GeneLink, Inc. Form 10-K for the Year Ended December 31, 2012 Filed April 1, 2013 Form 10-Q for the Quarter Ended March 31, 2013 Filed May 15, 2013 File No. 000-30518 Dear Ms. Cvrkel: We have responded to your comments below. Form 10-K for the Year Ended December 31, 2012 Au |
|
| September 5, 2013 |
September 5, 2013 Ms. Linda Cvrkel Branch Chief United States Securities and Exchange Commission Washington, D.C. 20549 Re: GeneLink, Inc. Form 10-K for the Year Ended December 31, 2012 Filed April 1, 2013 Form 10-Q for the Quarter Ended March 31, 2013 Filed May 15, 2013 File No. 000-30518 Dear Ms. Cvrkel: We have responded to your comments below and we have also attached a draft version of an ame |
|
| August 22, 2013 |
August 22, 2013 Ms. Linda Cvrkel Branch Chief United States Securities and Exchange Commission Washington, D.C. 20549 Re: GeneLink, Inc. Form 10-K for the Year Ended December 31, 2012 Filed April 1, 2013 Form 10-Q for the Quarter Ended March 31, 2013 Filed May 15, 2013 File No. 000-30518 Dear Ms. Cvrkel: This letter is to confirm the discussion between Michael Smith, Sr. VP of Operations at GeneLi |
|
| August 14, 2013 |
GeneLink GENELINK INC 10-Q 6-30-2013 (Quarterly Report) U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-30518 GENELINK, INC. (Exact name of regi |
|
| July 8, 2013 |
United States Securities and Exchange Commission Washington, DC 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: July 1, 2013 GeneLink, Inc. |
|
| June 12, 2013 |
8-K 1 v3476048k.htm FORM 8-K United States Securities and Exchange Commission Washington, DC 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: June 3, 2013 GeneLink, Inc. (Exact Name of Registrant as Specified in its Charter) PA 00-30518 23-2795613 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employe |
|
| May 15, 2013 |
GeneLink FORM 10-Q (Quarterly Report) U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-30518 GENELINK, INC. (Exact name of reg |
|
| May 2, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confid |
|
| April 10, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confid |
|
| February 12, 2013 |
United States Securities and Exchange Commission Washington, DC 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: February 8, 2013 GeneLink, Inc. |
|
| October 9, 2012 |
GNLKQ / GeneLink, Inc. / MARSHALL JON A - FORM SC 13D Activist Investment SC 13D 1 v325265sc13d.htm FORM SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) GeneLink, Inc. (Name of Issuer) Common Stock, $.01 par value per share (Title of Class of Securities) 36870F107 (CUSIP Number) Jon A Marshall 3330 Willowfork Place Katy, TX 77494 (713) 253-5473 (Name, Address and Telep |
|
| August 27, 2012 |
United States Securities and Exchange Commission Washington, DC 20549 Form 8-K/A Amendment No. |
|
| July 17, 2012 |
United States Securities and Exchange Commission Washington, DC 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: July 13, 2012 GeneLink, Inc. |
|
| May 15, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): £ Form 10-K ¨ Form 20-F ¨ Form 11-K S Form 10-Q ¨ Form N-SAR For Period Ended: March 31, 2012 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form N-SAR For Transition |
|
| May 11, 2012 |
United States Securities and Exchange Commission Washington, DC 20549 Form 8-K/A Amendment No. |
|
| May 10, 2012 |
GeneLink Reports 2011 Financial Results 2010 Re-audited and Restated GeneLink Reports 2011 Financial Results 2010 Re-audited and Restated Orlando, Florida – May 10, 2012 – GeneLink, Inc. |
|
| May 10, 2012 |
8-K 1 v3127698-k.htm FORM 8-K United States Securities and Exchange Commission Washington, DC 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: May 4, 2012 GeneLink, Inc. (Exact Name of Registrant as Specified in its Charter) PA 00-30518 23-2795613 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employe |
|
| May 4, 2012 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant - FORM 8-K/A United States Securities and Exchange Commission Washington, DC 20549 Form 8-K/A Amendment No. |
|
| May 4, 2012 |
EX-16 4 v312062ex16.htm EXHIBIT 16 May 4, 2012 Securities and Exchange Commission 450 Fifth Street, N.W. Washington, D.C. 20549 Ladies and Gentlemen: We have read the second and third paragraphs of Item 4.01 included in the Form 8-K/A of GeneLink, Inc. dated April 27, 2012 to be filed with the Securities and Exchange Commission and are in agreement with the statements contained therein. Very truly |
|
| May 4, 2012 |
May 4, 2012 VIA EDGAR CORRESPONDENCE Tia L. Jenkins Senior Assistant Chief Accountant Division of Corporation Finance United States Security and Exchange commission 100 F. Street, N.E. Washington, D.C. 20549 Re: GeneLink, Inc. Form 8-K Filed April 27, 2012 File No. 000-30518 Dear Ms. Jenkins, On behalf of GeneLink, Inc. (the “Company”), I am responding to the comments of the staff of the Division |
|
| April 27, 2012 |
8-K 1 v3110468-k.htm FORM 8-K United States Securities and Exchange Commission Washington, DC 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: April 24, 2012 GeneLink, Inc. (Exact Name of Registrant as Specified in its Charter) PA 00-30518 23-2795613 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Empl |
|
| April 27, 2012 |
GeneLink Anticipates Completion of Audit Trading Symbol Change Expected To Be Temporary GeneLink Anticipates Completion of Audit Trading Symbol Change Expected To Be Temporary Orlando, Florida – April 27, 2012 – On April 19, 2012, GeneLink's common stock began trading under the symbol "GNLKE" instead of “GNLK. |
|
| April 20, 2012 |
April 20, 2012 VIA EDGAR CORRESPONDENCE Tia L. Jenkins Senior Assistant Chief Accountant Division of Corporation Finance United States Security and Exchange commission 100 F. Street, N.E. Washington, D.C. 20549 Re: GeneLink, Inc. Form 8-K Filed March 20, 2012 File No. 000-30518 Dear Ms. Jenkins, We appreciate your prompt response in the matter of independence of recently appointed auditors, Cross |
|
| April 9, 2012 |
April 9, 2012 VIA EDGAR CORRESPONDENCE Tia L. Jenkins Senior Assistant Chief Accountant Division of Corporation Finance United States Securities and Exchange Commission 100 F. Street, N.E. Washington, D.C. 20549 Re: GeneLink, Inc. Form 8-K Filed March 20, 2012 File No. 000-30518 Dear Ms. Jenkins, On behalf of GeneLink, Inc. (the “Company”), I am responding to the comments of the staff of the Divis |
|
| March 30, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form N-SAR For Period Ended: December 31, 2011 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form N-SAR For Transiti |
|
| March 20, 2012 |
8-K 1 v3066138k.htm FORM 8-K United States Securities and Exchange Commission Washington, DC 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: March 14, 2012 GeneLink, Inc. (Exact Name of Registrant as Specified in its Charter) PA 00-30518 23-2795613 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Emplo |
|
| March 20, 2012 |
EX-16 2 v306613ex16.htm EXHIBIT 16 March 16, 2012 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on March 14, 2012, to be filed by our client, GeneLink, Inc. We agree with the statements made in response to that Item insofar as they relate to our Firm. Very truly you |
|
| March 20, 2012 |
Accounting for Sale of GeneWize and the Licensing and Distribution Agreement and Related Warrants Accounting for Sale of GeneWize and the Licensing and Distribution Agreement and Related Warrants Overview: In October 2011, GeneLink, Inc. |
|
| March 9, 2012 |
EX-16 2 v305455ex16.htm EXHIBIT 16 Exhibit 16 March 9, 2012 Securities and Exchange Commission 450 Fifth Street, N.W. Washington, D.C. 20549 Ladies and Gentlemen: We have read the first two paragraphs of Item 4 included in the Form 8-K of GeneLink, Inc. dated March 9, 2012 to be filed with the Securities and Exchange Commission and are in agreement with the statements contained therein. Very truly |
|
| March 9, 2012 |
8-K 1 v3054558k.htm FORM 8-K United States Securities and Exchange Commission Washington, DC 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: March 5, 2012 GeneLink, Inc. (Exact Name of Registrant as Specified in its Charter) PA 00-30518 23-2795613 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employ |
|
| February 16, 2012 |
United States Securities and Exchange Commission Washington, DC 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: February 10, 2012 GeneLink, Inc. |
|
| February 16, 2012 |
GENELINK BIOSCIENCES COMPLETES SALE OF GENEWIZE LIFE SCIENCES EXHIBIT 99.1 GENELINK BIOSCIENCES COMPLETES SALE OF GENEWIZE LIFE SCIENCES ORLANDO, FL – Feb. 16, 2012 – GeneLink Biosciences, Inc. (OTCBB:GNLK), a leading consumer genomics biotech company, has completed the sale of the stock of its wholly owned direct-selling subsidiary GeneWize Life Sciences, Inc. (GeneWize) to Capsalus Corp. (OTCBB:WELL), another public company operating in the health and well |
|
| January 31, 2012 |
United States Securities and Exchange Commission Washington, DC 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: January 25, 2012 GeneLink, Inc. |
|
| January 26, 2012 |
GNLKQ / GeneLink, Inc. / TRUSSELL ROBERT B JR Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) GeneLink, Inc. (Name of Issuer) Common Stock, $.01 par value per share (Title of Class of Securities) 36870F107 (CUSIP Number) Robert B. Trussell, Jr 167 W Main St Suite 1500 Lexington, KY 40507 (859) 226-0069 (Name, Address and Telephone Number of Person |
